Search

Your search keyword '"Tchérakian C"' showing total 45 results
Start Over Author "Tchérakian C"
45 results on '"Tchérakian C"'

1. Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial

Author

Devouassoux, G., Taillé, C., Chanez, P., Bonniaud, P., Bourdin, A., Saint Raymond, C., Maurer, C., Beurnier, A., Roux, P., Margelidon, V., Boudjemaa, A., Mangiapan, G., Freymond, N., Didi, T., Russier, M., Garcia, G., Meyer, E. Popin, Dupin, C., Fouquet, F., Jouveshomme, S., Gaspard, W., Dury, S., Maillard, S. Habib, Izadifar, A., Cuvillon, E., Deslée, G., Barnig, C., Perotin, J.M., Gamez, A.S., Oster, J.P., Khayat, N., Chenivesse, C., Li, X., Appere de Vecchi, C., Gicquello, A., Rami, H., Vignal, G., Just, N., Blanc, X., Leroyer, C., Wemeau, L., Achkar, A., Sattler, C., Catherinot, E., Guilleminault, L., Gaillot-Drevon, M., Rochefort-Morel, C., Couturaud, F., Martin, P., Chabrol, A., Pegliasco, H., Sése, L., Romanet, S., Caverstri, B., Tcherakian, C., Magnan, A., Ahmed, E., Allibe, F., Beltramo, G., Michaux, K., Paleiron, N., Martinez, S., Begne, C., Tummino, C., Givel, C., Mourin, G., Salvator, H., Volpato, M., Drucbert, M., Rossignoli, N., Keddache, S., Justet, A., Andrejak, C., Valcke, J., Perrin, J., Mercy, M., Jouvenot, M., Soumagne, T., Elharrar, X., Douvry, B., Godbert, B., Maitre, B., Goyard, C., Didier, A., Cadet, E., Chabot, F., Gonzalez, J., Mattei, L., Gouitaa, M., Chauveau, S., Raymond, S., Dirou, S., Fry, S., Briault, A., Moui, A., Paris, A., NoelSavina, E., Olivier, C., Caradec, E., Roche, N., Picart, G., Belmont, L., Portel, L., Serra, M. Rocca, Guibert, N., Jean, R., Hadjadj, S., Guillo, S., Gauquelin, L., Estellat, C., Prigent, A., Larrousse, M., Jaffuel, D., Bourayou, Karima, Klising, Eve, Yelles, Nessima, Pochon, Sarra, Gouider, Amal, Medina, Hadj Kaci, Yasmine, Sellali, Djouher, Dahmani, Ndao, Diakhou, Vacher, Yannick, Achkar, Antoine, Ahmed, Engi, Alain, Didier, Allibe, Flora, Andrejak, Claire, De Vecchi, Corinne Appere, Barnig, Cindy, Begne, Camille, Belmont, Laure, Beltramo, Guillaume, Blanc, Xavier, Briault, Amandine, Cadet, Emmanuelle, Caradec, Emmanuela, Catherinot, Émilie, Cavestri, Beatrice, Chabrol, Alexandre, Chanez, Pascal, Chauveau, Simon, Couturaud, Francis, Cuvillon, Édouard, Deslee, Gaëtan, Didi, Toufik, Dirou, Stéphanie, Douvry, benoît, Drucbert, Mélanie, Dupin, Clairelyne, Dury, Sandra, Elharrar, Xavier, Fouquet, Helen, Freymond, Nathalie, Fry, Stéphanie, Gaillot-Drevon, Maud, Gamez, Anne Sophie, Garcia, Gilles, Gaspard, Wanda, Gicquello, Alice, Givel, Claire, Godbert, benoit, Gonzalez, Jésus, Gouitaa, Marion, Goupil, François, Goyard, Céline, Guibert, Nicolas, Guilleminault, Laurent, Habib-Maillard, Stéphanie, Hadjadj, Samra, Izadifar, Armine, Jean, Romain, Jouvenot, marie, Jouveshomme, Stéphane, Just, Nicolas, Justet, Aurélien, Keddache, Sophia, Khayath, Naji, Lemaire, Bertrand, Leroyer, Christophe, Li, Xing, Magnan, Antoine, Maitre, Bernard, Mangiapan, Gilles, Margelidon, Victor, Martin, Pascale, Martinez, Stéphanie, Mattei, Laura, Maurer, Cyril, Mercy, Magalie, Michaux, Karine, Moui, Antoine, Mourin, Gisèle, Noel-Savina, Elisa, Olivier, Cécile, Oster, Jean-Philippe, Paleiron, Nicolas, Paris, Audrey, Pegliasco, Hervé, Perotin Collard, Jeanne-Marie, Perrin, Julie, Picart, Gaël, Pison, Christophe, Popin-Meyer, Élisabeth, Portel, Laurent, Rami, Hassina, Raymond, Stéphane, Serra, Mireille Rocca, Rochefort-Morel, Cécile, Romanet, Stéphanie, Rossignoli, Nadine, Roux, Pauline, Russier, Maud, Saint-Raymond, Christel, Salmeron, Sergio, Salvator, Helene, Sattler, Caroline, Sese, Lucile, Soumagne, Thibaud, Tcherakian, Colas, Tiotiu, Angélica, Tummino, Céline, Valcke-Brossollet, Judith, Vignal, Guillaume, Volpato, Mathilde, Wemeau, Lidwine, Valery, Solène, Simon-Tillaux, Noémie, Devouassoux, Gilles, Bonniaud, Philippe, Beurnier, Antoine, Boudjemaa, Amel, Chenivesse, Cécile, Bourdin, Arnaud, Gauquelin, Lisa, Guillo, Sylvie, Taillé, Camille, and Estellat, Candice

Published
2024
Full Text
View/download PDF

10. Hypertension pulmonaire postembolique

Author

Jais, X., Dartevelle, P., Parent, F., Sitbon, O., Humbert, M., Fadel, E., Mussot, S., Cabrol, S., Le Pavec, J., Sztrymf, B., Tcherakian, C., Musset, D., Maitre, S., and Simonneau, G.

Published
2007
Full Text
View/download PDF

13. Protéinose alvéolaire pulmonaire après allogreffe de cellules souches hématopoïétiques chez l’adulte : une enquête nationale française

Author

Salvator, H., Tcherakian, C., Maillard, N., Milin, S., Bergeron, A., Bondeelle, L., Meignin, V., N’guyen-Quoc, S., Souchet, L., Guenounou, S., Evrard, S., Rubio, M.T., Robin, M., Mediavilla, C., Brissot, E., Fajac, A., Catherinot, E., Givel, C., Chabrol, A., Goyard, C., Longchampt, E., Zemoura, L., Chabi-Charvillat, M.L., Bernaudin, J.F., and Couderc, L.J.

Published
2021
Full Text
View/download PDF

22. Impact des dilatations des bronches sur les caractéristiques cliniques et le pronostic des vascularites à ANCA : résultats d’une série de 61 patients

Author

Chilles, M., Lhote, R., Brillet, P.Y., Groh, M., Puechal, X., Cohen-Aubart, F., Delbre, X., Guilpain, P., Barda, T., De Boysson, H., Duhaut, P., Dominique, S., Hachulla, E., Hamidou, M., Subra, J.F., Lifermann, F., Fain, O., Cohen, P., Lhote, F., Nunes, H., Mathian, A., Catherinot, E., Terrier, B., Le Quellec, A., Legendre, C., Cottin, V., Amoura, Z., Couderc, L.J., Diot, E., Guillevin, L., and Tcherakian, C.

Published
2018
Full Text
View/download PDF

40. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases.

Author

Jais X, Launay D, Yaici A, Le Pavec J, Tchérakian C, Sitbon O, Simonneau G, and Humbert M

Abstract

OBJECTIVE: To describe the response to first-line immunosuppressive therapy with or without pulmonary vasodilators in pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD). METHODS: Twenty-three consecutive patients with SLE- or MCTD-associated PAH treated with first-line immunosuppressive therapy either alone (n = 16) or in combination with pulmonary vasodilators (n = 7) were evaluated according to clinical and hemodynamic criteria before and after immunosuppressive therapy. Responders were defined as patients in New York Heart Association (NYHA) functional class I or II with hemodynamic improvement after the last pulse of cyclophosphamide. RESULTS: Among the 16 patients treated with first-line immunosuppressive therapy alone, 8 (50%) were responders. These patients had a significantly improved NYHA functional class, 6-minute walking distance, and mean pulmonary artery pressure. Patients in NYHA functional class I or II and/or a cardiac index >3.1 liters/minute/m(2) at baseline were more likely to benefit from immunosuppressive therapy. Six of the 8 nonresponders subsequently improved with pulmonary vasodilators. Among the 7 patients who were initially treated with immunosuppressive therapy and pulmonary vasodilators, 4 (57.1%) were responders. CONCLUSION: PAH associated with SLE or MCTD may respond to a treatment combining cyclophosphamide and glucocorticoids. Patients who could benefit from this immunosuppressive therapy could be those who have less severe disease at baseline. For patients with more severe disease, pulmonary vasodilators should be started, possibly in combination with immunosuppressants. In any case, clinical and hemodynamic evaluations are mandatory to monitor the response and adapt the treatment. These retrospective and uncontrolled data need to be confirmed by randomized controlled trials. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

42. IgG4-related disease and hypereosinophilic syndrome: Overlapping phenotypes.

Author

Moussiegt A, Müller R, Ebbo M, Grados A, Graveleau J, Ackermann F, Bachmeyer C, Bernit E, Blanche P, Canoui E, Chaix F, Costedoat-Chalumeau N, Groote P, Etienne N, Fior R, Flamarion E, Kennel T, Launay D, Lerolle N, Limal N, Loustau V, Menage E, Moulis G, Papo T, Pouchot J, Quemeneur T, Roumier M, Tchérakian C, Lefèvre G, Rebours V, Kahn JE, Schleinitz N, and Groh M

Subjects
Humans, Phenotype, Rituximab, Hypereosinophilic Syndrome diagnosis, Hypereosinophilic Syndrome genetics, Immunoglobulin G4-Related Disease diagnosis
Published
2021
Full Text
View/download PDF

43. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.

Author

Roumier M, Paule R, Vallée A, Rohmer J, Ballester M, Brun AL, Cerf C, Chabi ML, Chinet T, Colombier MA, Farfour E, Fourn E, Géri G, Khau D, Marroun I, Ponsoye M, Roux A, Salvator H, Schoindre Y, Si Larbi AG, Tchérakian C, Vasse M, Verrat A, Zuber B, Couderc LJ, Kahn JE, Groh M, and Ackermann F

Subjects
Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, COVID-19 diagnosis, Combined Modality Therapy, Disease Progression, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Propensity Score, Receptors, Interleukin-6 antagonists & inhibitors, Severity of Illness Index, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, COVID-19 virology, SARS-CoV-2 drug effects, COVID-19 Drug Treatment
Abstract

Background: High levels of serum interleukin-6 (IL-6) correlate with disease severity in COVID-19. We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) could improve outcomes in selected patients with severe worsening COVID-19 pneumonia and high inflammatory parameters., Methods: The TOCICOVID study included a prospective cohort of patients aged 16-80 years with severe (requiring > 6 L/min of oxygen therapy to obtain Sp02 > 94%) rapidly deteriorating (increase by ≥ 3 L/min of oxygen flow within the previous 12 h) COVID-19 pneumonia with ≥ 5 days of symptoms and C-reactive protein levels > 40 mg/L. They entered a compassionate use program of treatment with intravenous tocilizumab (8 mg/kg with a maximum of 800 mg per infusion; and if needed a second infusion 24 to 72 h later). A control group was retrospectively selected with the same inclusion criteria. Outcomes were assessed at D28 using inverse probability of treatment weighted (IPTW) methodology., Results: Among the 96 patients included (81% male, mean (SD) age: 60 (12.5) years), underlying conditions, baseline disease severity, and concomitant medications were broadly similar between the tocilizumab (n = 49) and the control (n = 47) groups. In the IPTW analysis, treatment with tocilizumab was associated with a reduced need for overall ventilatory support (49 vs. 89%, wHR: 0.39 [0.25-0.56]; p < 0.001). Albeit lacking statistical significance, there was a substantial trend towards a reduction of mechanical ventilation (31% vs. 45%; wHR: 0.58 [0.36-0.94]; p = 0.026). However, tocilizumab did not improve overall survival (wHR = 0.68 [0.31-1.748], p = 0.338). Among the 85 (89%) patients still alive at D28, patients treated with tocilizumab had a higher rate of oxygen withdrawal (82% vs. 73.5%, wHR = 1.66 [1.17-2.37], p = 0.005), with a shorter delay before being weaned of oxygen therapy (mean 11 vs. 16 days; p < 0.001). At D28, the rate of patients discharged from hospital was higher in the tocilizumab group (70% vs. 40%, wHR = 1.82 [1.22-2.75]; p = 0.003). The levels of CRP and fibrinogen post therapy (p < 0.001 for both variables) were significantly lower in the tocilizumab group (interaction test, mixed model). Rates of neutropenia (35% vs. 0%; p < 0.001) were higher in the tocilizumab group, yet rates of infections (22% vs. 38%, p = 0.089) including ventilator-acquired pneumonia (8% vs. 26%, p = 0.022) were higher in the control group., Conclusion: These data could be helpful for the design of future trials aiming to counter COVID-19-induced inflammation, especially before patients require admission to the intensive care unit.

Published
2021
Full Text
View/download PDF

44. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.

Author

Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, Marie I, Khellaf M, Kahn JE, Karras A, Ziza JM, Deligny C, Tchérakian C, and Guillevin L

Subjects
Adult, Aged, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis epidemiology, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis mortality, Antibodies, Monoclonal, Murine-Derived adverse effects, Antirheumatic Agents adverse effects, Bacterial Infections epidemiology, Female, France epidemiology, Humans, Longitudinal Studies, Male, Middle Aged, Remission Induction, Retrospective Studies, Risk Factors, Rituximab, Survival Rate, Treatment Outcome, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antirheumatic Agents therapeutic use, Disease Management
Abstract

Objectives: Rituximab has been shown to induce remission of ANCA-associated vasculitides (AAVs). Our study was undertaken to describe AAV clinical responses to rituximab used for remission-induction and/or maintenance therapy, assess rituximab's safety profile and evaluate French clinical practices., Methods: This retrospective study concerned AAV patients who had received one or more rituximab infusion between 2002 and January 2011 and had follow-up lasting ≥12 months., Results: Eighty patients were included, most with refractory or relapsing AAV: 70 (88%) with granulomatosis with polyangiitis (GPA), 9 (11%) with microscopic polyangiitis and 1 (1%) with eosinophilic GPA. Rituximab was the first agent used to induce remission in 73 patients. The two most commonly administered regimens were an infusion of 375 mg/m(2)/week for 4 weeks (54 patients) and an infusion of 1 g every 2 weeks for a month (16 patients). Rituximab was first prescribed to maintain remission in seven patients. Respective 1-, 2-, and 3-year relapse-free survival rates after the first infusion were 80% (95% CI 72, 89), 63% (51, 77) and 52% (39, 70). Relapse-free survival was longer for patients receiving rituximab maintenance therapy (P = 0.002). Among 22 (28%) rituximab-treated patients experiencing severe adverse events, 12 (15%) had infectious complications leading to 4 (5%) deaths. Only 15 (19%) patients had received anti-pneumococcal vaccine before rituximab., Conclusion: Rituximab was able to induce AAV remission and seemed to maintain remission better than other agents, but caution is needed concerning its safety, especially regarding bacterial infections, in this population.

Published
2014
Full Text
View/download PDF

45. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Author

Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, and Humbert M

Subjects
Adult, Aged, Antihypertensive Agents adverse effects, Bosentan, Drug Administration Schedule, Drug Therapy, Combination, Endothelin A Receptor Antagonists, Epidemiologic Methods, Epoprostenol therapeutic use, Exercise Test methods, Female, Hemodynamics drug effects, Humans, Hypertension, Pulmonary etiology, Hypertension, Pulmonary physiopathology, Iloprost therapeutic use, Male, Middle Aged, Piperazines therapeutic use, Purines therapeutic use, Scleroderma, Systemic physiopathology, Sildenafil Citrate, Sulfonamides adverse effects, Sulfones therapeutic use, Treatment Outcome, Antihypertensive Agents therapeutic use, Hypertension, Pulmonary drug therapy, Scleroderma, Systemic complications, Sulfonamides therapeutic use
Abstract

Objective: Data on long-term efficacy of bosentan, an oral dual ET receptor antagonist, in SSc-associated pulmonary arterial hypertension (SSc-PAH) are lacking. We aimed to describe the long-term outcome of SSc-PAH treated with first-line monotherapy bosentan followed or not by the addition of prostanoids or sildenafil., Methods: A prospective analysis of 49 consecutive SSc-PAH patients treated with first-line bosentan was performed. New York Heart Association (NYHA) functional class, 6-min walk distance (6MWD) and haemodynamics were assessed at baseline and after 4 and 12 months., Results: At 4 months, significant improvements in NYHA functional class and haemodynamics were observed with stabilization at 1 year. There was no significant improvement in 6MWD. Overall survival estimates were 80, 56 and 51% at 1, 2 and 3 years, respectively, and were significantly worse than those in a cohort of patients with idiopathic PAH (92, 89 and 79% at 1, 2 and 3 years, respectively; P < 0.0001). Twenty-three patients (47%) died after a mean follow-up of 23 (18) months. In multivariate analysis, baseline and 4-month NYHA functional class and 4-month cardiac index were independent factors associated with overall survival., Conclusions: In our cohort of consecutive SSc-PAH patients treated with first-line bosentan, improvement in NYHA functional class and haemodynamics was significant after 4 months of treatment and stabilized afterwards. One-year overall survival rate was higher than previously reported in historical series. However, long-term prognosis remains poor. Our study underlines the importance of haemodynamic evaluation 4 months after the start of treatment to provide strong parameters associated with survival-like cardiac index.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results